PARP
PARP-1 (poly(ADP-ribose) polymerase 1) is a nuclear ADP-ribosyl transferase that functions as an early sensor of DNA strand breaks and coordinates cellular responses to genomic damage through poly(ADP-ribosyl)ation-dependent signaling[1][2]. Mechanistically, PARP-1 participates in multiple DNA repair pathways, including base excision repair (BER), homologous recombination (HR), and non-homologous end joining (NHEJ), where it promotes chromatin remodeling and recruitment of repair factors to damaged DNA sites[1][2][3]. Through these activities, PARP-1 contributes to genome surveillance and maintenance of genomic stability, processes that are frequently disrupted during tumor development[1][2]. In cancer biology, dysregulated PARP-1 function has been associated with disease progression, and inhibition of PARP-mediated DNA repair can reduce tumor cell viability by exploiting defects in homologous recombination repair pathways[1][4]. Compared with the closely related isoform PARP-2, PARP-1 is the dominant mediator of single-strand break repair, whereas PARP-2 shares DNA repair functions but also displays distinct roles in biological processes including inflammation, metabolism, oxidative stress responses, and cancer progression[3][5]. This functional distinction is important for understanding isoform-specific biology and for designing selective therapeutic strategies[5]. For experimental and translational applications, PARP inhibitors have become widely used tools to interrogate DNA damage responses and to target tumors with DNA repair deficiencies, particularly those characterized by homologous recombination defects[1][4].
References:
- [1]. Conceição CJF, et al. PARP1: A comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments. Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189282. [Content Brief]
- [2]. Pazzaglia S, et al. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases. Cells. 2020;9(1):41.
- [3]. Szántó M, et al. Specific and shared biological functions of PARP2 - is PARP2 really a lil' brother of PARP1? Expert Rev Mol Med. 2024;26:e13.
- [4]. Rose M, et al. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020 Sep 9;8:564601. [Content Brief]
- [5]. Yelamos J, et al. PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res. 2011;1(3):328-346. Epub 2011 Jan 8. PMID: 21968702; PMCID: PMC3180065. [Content Brief]
All Product Categories
-
PARP Related Products (307)
Related Products (307)
-
Antibodies (2)
-
Theophylline-platinum(IV) prodrug-1
0 ImagesCat. No.: HY-175257Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer.
-
HYDAMTIQ
0 ImagesCat. No.: HY-155458CAS No.: 1201832-32-7HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more.
-
Continentalic acid (Standard)
0 ImagesCat. No.: HY-N6908RCAS No.: 19889-23-7Continentalic acid (Standard) is the analytical standard of Continentalic acid (HY-N6908). This product is intended for research and analytical applications. Continentalic acid is a diterpenoid organic acid. Continentalic acid exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial and antitumor effects. Continentalic acid alleviates oxidative stress, reduces pro-inflammatory cytokine production, inhibits MAPK phosphorylation and neutrophil infiltration, and induces growth inhibition and apoptosis of cancer cells. Continentalic acid can be used in research related to traumatic brain injury, cancer, inflammation and infections.
-
Paris saponin VII (Standard)
0 ImagesCat. No.: HY-N3584RCAS No.: 68124-04-9Synonyms: Chonglou Saponin VII (Standard)Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.
-
PARP1-IN-27
0 ImagesCat. No.: HY-161934PARP1-IN-27 (Compound 9B) is the inhibitor for PARP1 and PARP2, with IC50 of 2.53 nM and 6.45 nM in cell SUM149PT. PARP1-IN-27 inhibits the proliferation of BRCA-mutated cancer cells SUM149PT, HCC1937 and Capan-1, with IC50 of 0.62, 1.91 and 4.26 μM respectively. PARP1-IN-27 aggravates DNA double-strand breaks, increases ROS generation, arrests cell cycle at G2/M phase, and induces apoptosis in SUM149PT.
-
Ru3
0 ImagesCat. No.: HY-155348Ru3 is a poly(ADP-ribose) polymerase 1 inhibitor. Ru3 induces apoptosisin MCF-7 cells by multiple modes, inclusive of inducing DNA damage, suppressing DNA damage repair, disturbing cell cycle distribution, decreasing the mitochondrial membrane potential, and increasing the intracellular reactive oxygen species levels.
-
ADPRP
0 ImagesCat. No.: HY-134355CAS No.: 53595-18-9ADPRP is an intranuclear enzyme whose main activity is to use NAD+ (nicotinamide adenine dinucleotide) as a substrate to add ADP-ribose units to chromatin-bound proteins, including the ADPRP enzyme itself. This process, called poly(ADP-ribosylation), is a post-translational modification that regulates the interaction between DNA and nuclear proteins.
-
TNKS-IN-2
0 ImagesCat. No.: HY-117700CAS No.: 1584646-59-2TNKS-IN-2 (compound 40) is a potent and selective tankyrase (TNKS) inhibitor with pIC50 values of 8.1, 7.0 for TANKS and Wnt, respectively.
-
PARP1-IN-6
0 ImagesCat. No.: HY-139879CAS No.: 1654735-36-0PARP1-IN-6 is a dual tubulin/PARP-1 inhibitor with IC50 values of 0.94 and 0.48 μM, respectively.
-
PI3K/AKT-IN-4
0 ImagesCat. No.: HY-162802PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets.
-
Antitumor agent-72
0 ImagesCat. No.: HY-150696CAS No.: 2676942-92-8Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research.
-
Lotixparib
0 ImagesCat. No.: HY-177100CAS No.: 2640677-63-8Lotixparib (Example 1) is an inhibitor of poly(ADP-ribose)polymerase-1 (PARP-1). Lotixparib has cytoprotective effect against a retinal disease. Lotixparib can be studied in research for PARP-1-associated diseases.
-
KB-15
0 ImagesCat. No.: HY-175542KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer.
-
CDK9-IN-47
0 ImagesCat. No.: HY-182069CDK9-IN-47 is an orally active and selective CDK9 inhibitor with an IC50 of 1.4 nM. CDK9-IN-47 inhibits tumor cell proliferation, migration and invasion, and induces apoptosis. CDK9-IN-47 can be used for the research of triple-negative breast cancer.
-
2-Chlorohexadecanoic acid (Standard)
0 ImagesCat. No.: HY-131688RCAS No.: 19117-92-1Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis.
